Andrew J Pierce
9PUBLICATIONS
85CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (9)
Sort by Publication Date:
|Mar 17, 2025
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.Johann S de Bono, Anja Williams, Ignacio Melero
|Jul 19, 2024
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.Luisa Chocarro, Ester Blanco, Leticia Fernandez-Rubio
|Apr 09, 2024
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.Sophie Archer, Phillip M Brailey, Minjung Song
|Feb 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar
|Dec 31, 2021
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.Carolyn J Edwards, Angelica Sette, Carl Cox
|Oct 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.Sophie E Willis, Claudia Winkler, Martine P Roudier
Pageof 2
Frequent Collaborators
2 joint publications
Philip Bland-Ward
2 joint publications
Johann S de Bono
2 joint publications
James Legg
2 joint publications
Phillip D Bartlett
2 joint publications
Neil R Birkett
1 joint publications
Peter Mortimer
1 joint publications
Kyoung-Mee Kim
1 joint publications
Timothy A Yap
1 joint publications
Matthew G Krebs
1 joint publications
Jeffrey R Whiteaker
